Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349976 | 0.91 | HSP90AB1 (0.42) | HSP90AB1HSP90AA1NOS3NOS1NOS2 | |
| SCHEMBL17349442 | 0.82 | HSP90AA1 (0.51) | HSP90AB1HSP90AA1HRH2HRH3DHFR | |
| SCHEMBL23153346 | 0.81 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1NOS3NOS1NOS2 | |
| SCHEMBL23153308 | 0.75 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1NOS3NOS1CYP2C19 | |
| SCHEMBL17336036 | 0.74 | HRH2 (0.46) | HSP90AB1HSP90AA1HRH2HRH3DHFR | |
| SCHEMBL17349619 | 0.74 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1NOS3NOS1NOS2 | |
| SCHEMBL18750348 | 0.74 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1NOS3NOS1NOS2 | |
| SCHEMBL14209035 | 0.74 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1NOS3NOS1CYP2C19 | |
| SCHEMBL17349606 | 0.73 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1NOS3NOS1CYP2C19 | |
| SCHEMBL24055078 | 0.73 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1NOS3NOS1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154547-B1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3154547-B1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| EP-3154547-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | Yuma Therapeutics, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885NOS3 4287/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | HSP90AB1 4/4885HSP90AA1 7/4885NOS3 4509/4885 |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885NOS3 4287/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | HSP90AB1 5/4885HSP90AA1 8/4885NOS3 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.